Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant Patients

  • Atara Biotherapeutics Inc ATRA has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel (tab-cel) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ transplantation (SOT).
  • Results were presented at the American Transplant Congress.
  • Combined objective response rate (ORR) and OS data across two SOT subgroups – relapsed or refractory to rituximab (R/R) monotherapy and R/R to rituximab + chemotherapy (CT) – showed one and 2-year OS for patients achieving either complete response (CR) or those achieving a partial response (PR).
  • All patients with a complete response or a partial response to tab-cel were alive at one year.
  • Tab-cel was well-tolerated, and no emerging safety concerns and no instances of tumor flare reaction, infusion-related reactions, graft versus host disease, cytokine release syndrome, neurotoxicity, or organ rejection were reported.
  • Price Action: ATRA shares are up 5.42% at $13.89 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!